Clinical trials: Letrozole
Breast Cancer, Osteoporosis
Letrozole With or Without Zoledronate in Treating Healthy Postmenopausal Women With High Breast Density
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. Estrogen can cause the growth of breast cancer cells.
- Trial name
- NCT00114270
- Testing
- letrozole, zoledronic acid
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Virginia
Breast Cancer
RADIANT: Pre-op Radiation With Abemaciclib and Letrozole
This phase 1b study investigates the safety and feasibility of combining pre-operative radiation therapy with Cyclin-Dependent Kinase 4 (CDK4/6) inhibitors in participants with hormone receptor positive/HER2 negative (HR+/HER2-)…
- Trial name
- NCT06139107
- Testing
- Abemaciclib, Letrozole
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Mridula George, MD
Female Infertility Due to Nonimplantation of Ovum
Letrozole and Sequential Clomiphene to Improve the Outcome of Embryo Transfer
The purpose of this study is to study the effects of letrozole and sequential clomiphene in ovulation and pregnancy in PCOS patients.
- Trial name
- NCT02775877
- Testing
- Letrozole, clomiphene, HMG
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Navy General Hospital, Beijing
Breast Cancer
Effectiveness of Zoledronic Acid in the Prevention of Osteoporosis in Early Breast Cancer Patients Receiving Letrozole
The purpose of this study is to determine whether zoledronic acid given intravenously every 6 months can prevent reduction in bone mineral density in women with early stage breast cancer receiving adjuvant therapy with the…
- Trial name
- NCT00376740
- Testing
- zoledronic acid
- Where
- 2 sites in Israel
- Volunteers
- 90 people
- Sponsor
- Soroka University Medical Center
Metastatic or Locally-advanced Unresectable Breast Cancer
BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer
The purpose of this study is to test the safety of a drug called BYL719 at different dose levels. The investigators want to find out what effects, good and/or bad, BYL719 has on the patient and breast cancer.
- Trial name
- NCT01870505
- Testing
- BYL719, Letrozole, Exemestane
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Healthy
Food Study of Letrozole Tablets 2.5 mg and Femara® Tablets 2.5 mg
The objective of this study was to investigate the bioequivalence of Mylan's letrozole 2.5 mg tablets to Novartis' Femara® 2.5 mg tablets following a single, oral 2.5 mg (1 x 2.5 mg) dose administered under fed conditions.
- Trial name
- NCT00648154
- Testing
- Letrozole Tablets 2.5 mg, Femara® Tablets 2.5 mg
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Mylan Pharmaceuticals Inc
Breast Cancer
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer
The main purpose of this study is to evaluate the efficacy of the study drug abemaciclib in postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) locoregionally…
- Trial name
- MONARCH plus (NCT02763566)
- Testing
- Abemaciclib, Anastrozole, Letrozole
- Where
- 45 sites in Brazil, China and 2 more
- Volunteers
- 463 people
- Sponsor
- Eli Lilly and Company
Advanced Breast Cancer
A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer
This is a Phase III clinical trial designed to evaluate the efficacy and safety of XZP-3287 in combination with Letrozole/Anastrozole versus placebo in combination with Letrozole/Anastrozole in patients with HR-positive and…
- Trial name
- NCT05257395
- Testing
- XZP-3287+ Letrozole/Anastrozole
- Where
- China
- Volunteers
- 397 people
- Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
Breast Cancer
Neoadjuvant Combined Endocrine and HER2 Target Therapy in Postmenopausal Women With ER and Her2 Positive Breast Cancer
Cross-talk between epidermal growth factors and the ER occurs at multiple levels and seems to play a crucial role in breast cancer progression and endocrine resistance.Combined HER1/HER2-targeted therapy with aromatase inhibitors…
- Trial name
- Neo-All-In (NCT01275859)
- Testing
- Letrozole, Lapatinib
- Where
- South Korea
- Volunteers
- 25 people
- Sponsor
- Asan Medical Center
is to Identify Biomarkers That Could Predict the Efficacy of an Adjuvant Letrozol Treatment in Postmenopausal Breast Cancer Patients.
Evaluation of Predictive Factors Regarding the Effectivity of Aromatase Inhibitor Therapy (PreFace)
Aromatase inhibitors have shown a superior efficacy compared to tamoxifen in the treatment of hormonal receptor positive breast cancer in postmenopausal patients.
- Trial name
- PreFace (NCT01908556)
- Testing
- Letrozole
- Where
- Germany
- Volunteers
- 3,545 people
- Sponsor
- Institut fuer Frauengesundheit
Breast Cancer
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Eligible patients will be post-menopausal hormone receptor- and lymph node-positive females who recently underwent primary surgery for breast cancer.
- Trial name
- FACE (NCT00248170)
- Testing
- Letrozole, Anastrozole
- Where
- 259 sites in United States, Australia and 18 more
- Volunteers
- 4,172 people
- Sponsor
- Novartis Pharmaceuticals
Breast Neoplasms
A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)
The study is designed to compare the clinical benefit following treatment with letrozole in combination with PD-0332991 versus letrozole in combination with placebo in postmenopausal women with ER(+)/HER2(-) advanced breast…
- Trial name
- NCT01740427
- Testing
- PD-0332991, Letrozole
- Where
- 305 sites in United States, Australia and 16 more
- Volunteers
- 666 people
- Sponsor
- Pfizer
Healthy
Bioavailability Study of Letrozole Tablets 2.5 mg of Dr.Reddy's Under Fed Conditions
The purpose of this study is to compare bioavailability in healthy, post menopausal women subjects under fed conditions.
- Trial name
- NCT01372982
- Testing
- Letrozole
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited